Physician profile
Kyle Glover
NPI 1801381504
$1,175.04
in general payments reported to CMS, 2019-2025
16 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $281 · 2022: $99.56 · 2023: $263 · 2024: $231 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $299.82 | 2021-2024 | |
| Biotronik Nro, INC. | $222.08 | 2025 | Prospera |
| Novo Nordisk INC | $183.45 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $131.62 | 2023-2025 | |
| Amgen INC. | $50.41 | 2021-2023 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $42.34 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $34.65 | 2022-2023 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $32.21 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $28.02 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $25.65 | 2021 | |
| Glaxosmithkline, LLC. | $23.40 | 2024 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.22 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $21.32 | 2021 | |
| Eisai INC. | $20.60 | 2021 | |
| Amarin Pharma, INC. | $19.90 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.35 | 2024 | Jardiance, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Glover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.